Every article, report, and earnings note where BIIB appears.
Biogen’s business has stabilized, with growth products and LEQEMBI helping offset legacy MS pressure. The stock still looks reasonably priced for a selective Buy as cash flow and mix improve.
Biogen’s selloff looks backward-looking. A newly approved home-start LEQEMBI formulation and fresh real-world stability data make the Alzheimer’s story easier to scale, not harder to believe.
Biogen Inc. (BIIB) drops sharply after mixed Phase 2 Alzheimer’s trial results for diranersen, also known as BIIB080. The stock fell on heavy volume as investors focused on the missed primary endpoint, even though the study showed encouraging biomarker and cognitive signals and the program may still advance.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate BIIB ReportCancel anytime